![[ Back to EurekAlert! ]](https://lh3.googleusercontent.com/blogger_img_proxy/AEn0k_vRY10RD68J_Vdt1-AO9JpP1uUfQf0R1pdfjJp1QeiMPjA-kEcnhnnGRy-ghNs_aXiZmyCJc0FO4iTSEVfBO-qNNLZIb8XBS7TAVAhVZSs=s0-d){kind=small}
Public release date: 29-Oct-2012[ | E-mail |
Share ] Contact: Joe Dangor
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
BOSTON -- An oral rinse of the antidepressant doxepin significantly eased pain associated with oral mucositis in patients receiving radiation therapy for cancers of the head and neck, a study led by Mayo Clinic found. The findings were presented at the American Society for Radiation Oncology annual meeting in Boston.
MULTIMEDIA ALERT: A video interview with Dr. Miller is available for journalists to download on the Mayo Clinic News Network.
"Oral mucositis or mouth sores is a painful and debilitating side effect of radiation therapy," says principal investigator Robert Miller, M.D., a radiation oncologist at Mayo Clinic. "Our findings represent a new standard of care for treating this condition."
Doxepin rinse does not cause the side effects associated with narcotic pain medicines, Dr. Miller says.
The Phase III study assessed the effectiveness of doxepin oral rinse versus placebo in 155 patients receiving radiation therapy for head and neck cancer. Patients received a single blinded dose of doxepin on day one and crossed over to the opposite study arm on a subsequent day. Patients reported pain associated with oral mucositis on a pain questionnaire with a scale of 0 to 10 administered at baseline and then at five, 15, 30, 60, 120 and 240 minutes after rinsing with doxepin. Patients could continue doxepin after the study, and 64 percent did so. Doxepin was well tolerated, though stinging, burning, unpleasant taste and drowsiness were reported as side effects.
###
Mayo Clinic researchers involved in the study also included Rui Qin, Ph.D., James Martenson, M.D., Robert Foote, M.D. and Charles Loprinzi, M.D.
About Mayo Clinic Cancer Center
As a leading institution funded by the National Cancer Institute, Mayo Clinic Cancer Center conducts basic, clinical and population science research, translating discoveries into improved methods for prevention, diagnosis, prognosis and therapy. For information on cancer clinical trials, call 507-538-7623.
About Mayo Clinic
Mayo Clinic is a nonprofit worldwide leader in medical care, research and education for people from all walks of life. For more information, visit MayoClinic.com or MayoClinic.org/news.
[ | E-mail | Share ] ?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Public release date: 29-Oct-2012[ | E-mail |
Share ] Contact: Joe Dangor
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
BOSTON -- An oral rinse of the antidepressant doxepin significantly eased pain associated with oral mucositis in patients receiving radiation therapy for cancers of the head and neck, a study led by Mayo Clinic found. The findings were presented at the American Society for Radiation Oncology annual meeting in Boston.
MULTIMEDIA ALERT: A video interview with Dr. Miller is available for journalists to download on the Mayo Clinic News Network.
"Oral mucositis or mouth sores is a painful and debilitating side effect of radiation therapy," says principal investigator Robert Miller, M.D., a radiation oncologist at Mayo Clinic. "Our findings represent a new standard of care for treating this condition."
Doxepin rinse does not cause the side effects associated with narcotic pain medicines, Dr. Miller says.
The Phase III study assessed the effectiveness of doxepin oral rinse versus placebo in 155 patients receiving radiation therapy for head and neck cancer. Patients received a single blinded dose of doxepin on day one and crossed over to the opposite study arm on a subsequent day. Patients reported pain associated with oral mucositis on a pain questionnaire with a scale of 0 to 10 administered at baseline and then at five, 15, 30, 60, 120 and 240 minutes after rinsing with doxepin. Patients could continue doxepin after the study, and 64 percent did so. Doxepin was well tolerated, though stinging, burning, unpleasant taste and drowsiness were reported as side effects.
###
Mayo Clinic researchers involved in the study also included Rui Qin, Ph.D., James Martenson, M.D., Robert Foote, M.D. and Charles Loprinzi, M.D.
About Mayo Clinic Cancer Center
As a leading institution funded by the National Cancer Institute, Mayo Clinic Cancer Center conducts basic, clinical and population science research, translating discoveries into improved methods for prevention, diagnosis, prognosis and therapy. For information on cancer clinical trials, call 507-538-7623.
About Mayo Clinic
Mayo Clinic is a nonprofit worldwide leader in medical care, research and education for people from all walks of life. For more information, visit MayoClinic.com or MayoClinic.org/news.
[ | E-mail | Share ] ?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Source: http://www.eurekalert.org/pub_releases/2012-10/mc-mca102312.php
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.